干扰素α治疗对慢性乙型肝炎患者外周血树突状细胞抗原提呈作用的影响

目的　探讨干扰素α治疗对慢性乙型肝炎患者外周血树突状细胞 (DC)抗原提呈作用的影响。方法　分别采集 2 3例慢性乙型肝炎患者干扰素α治疗前和治疗满 4个月时的抗凝外周静脉血 ,分离外周血单个核细胞 (PBMC) ,在重组人白细胞介素 4和重组人粒细胞 巨噬细胞集落刺激因子的作用下培养 7d使DC增殖、成熟 ,随后与HBsAg共同孵育 3h ,丝裂霉素C处理后再分别与自体PBMC共同培养 72h ,培养结束前 1 2h加入 7 4× 1 0 4Bq3 H TDR ,收集细胞测定cpm值。实验中以 8名正常健康人作为对照。结果　干扰素α治疗 4个月时慢性乙型肝炎患者DC的增殖水平明显高于治疗前 ,在相同培养条件下 ,细胞总量平均增加了 2 .8倍 ;治疗前DC的抗原提呈作用显著低于健康对照组和治疗后组 (均为P <0 .0 0 1 ) ,治疗 4个月时DC的抗原提呈作用与健康对照组之间差异无显著意义 (P >0 .0 5 ) ;进一步分析发现 ,与无应答组比较 ,完全应答组不论是治疗前还是治疗后 ,DC的抗原提呈作用均显著增强 (P <0 .0 1和P <0 .0 0 1 ) ,而部分应答组与无应答组之间差异无显著意义(P >0 .0 5 )。结论　慢性乙型肝炎患者外周血DC的抗原提呈能力低下 ,干扰素α治疗可显著提高DC的抗原提呈作用 ,并且DC的抗原提呈能力似乎与患者对干扰素α的应答密切相关

Effect of interferon-alpha therapy on the capacity of antigen presenting of peripheral blood dendritic cells from patients with chronic hepatitis B

OBJECTIVE: To study the effect of interferon -alpha therapy on the capacity of antigen presenting of peripheral blood dendritic cells from patients with chronic hepatitis B (CHB). METHODS: The peripheral blood samples were obtained from 23 patients who were given interferon-alpha therapy just before treatment and after treatment for 4 months, respectively. The peripheral blood mononuclear cells (PBMC) were isolated and cultured, and recombinant human IL-4 and GM-CSF were added to the cultures. After cultured for 7 days, dendritic cells (DC) were harvested and then incubated with HBsAg for 3 hours, then mixed with autogenous PBMC and cocultured for additional 72 hours. Before ending the culiration, 7.4 x 10(4) Bq (3)H-TDR was added to the culture for 12 hours, and then all cells were collected and detected for cpm values. Eight healthy individuals were used as controls. RESULTS: After treatment for 4 months with interferon-alpha, the proliferating level of DC markedly increased in posttreatent group when compared with that in the pretreatment group and the total number of DC proliferation averagely increased 2.8 times in the same culture condition. The capacity of antigen presenting of DC in the pretreatment group markedly decreased compared with that either in posttreatment group or in healthy group, respectively (P < 0.001), and there was no significant difference between the posttreatment group and the healthy group (P > 0.05). Both before and after treatment the capacities of DC antigen presenting in interferon-alpha complete responder group were significantly stronger than those in the nonresponder group (P < 0.01 and P < 0.001). There was no significant difference between the partial responder group and nonresponder one (P > 0.05). CONCLUSION: The results indicate the capacity of antigen presenting of peripheral blood DC from CHB patients is dysfunctional. Interferon-alpha therapy may markedly improve the capacity. The potential of antigen presenting of DC in CHB patients may be closely correlated with the response to interferon-alpha therapy.